Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer.
about
Mechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome ItFrom bench to bedside: What do we know about hormone receptor-positive and human epidermal growth factor receptor 2-positive breast cancer?c-Src-null mice exhibit defects in normal mammary gland development and ERalpha signalingStrategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials.Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence.Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer.Complexity of signal transduction mediated by ErbB2: clues to the potential of receptor-targeted cancer therapy.Tamoxifen resistance and Her2/neu expression in an aged, irradiated rat breast carcinoma model.Deconstructing the molecular portraits of breast cancer.Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells.Testing for HER2 in Breast Cancer: A Continuing Evolution.Even low-level HER2 expression may be associated with worse outcome in node-positive breast cancer.Protein kinase D1 regulates ERα-positive breast cancer cell growth response to 17β-estradiol and contributes to poor prognosis in patientsRole of steroid hormones and growth factors in breast cancer.Differential gene expression patterns in HER2/neu-positive and -negative breast cancer cell lines and tissuesPoor-prognosis estrogen receptor- positive disease: present and future clinical solutionsActivated HER-receptors in predicting outcome of ER-positive breast cancer patients treated with adjuvant endocrine therapyER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer.Cyclin A is a prognostic indicator in early stage breast cancer with and without tamoxifen treatment.A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer.The role of Herceptin in early breast cancerAdditive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182,780) in breast cancer cellsTGF-beta signaling in breast cancer.AKT-aro and HER2-aro, models for de novo resistance to aromatase inhibitors; molecular characterization and inhibitor response studiesDo type 1 receptor tyrosine kinases inform treatment choice? A prospectively planned analysis of the TEAM trialUpdate on the use of aromatase inhibitors in early-stage breast cancer.Management of metastatic HER2-positive breast cancer progression after adjuvant trastuzumab therapy - current evidence and future trends.The potential use of expression profiling: implications for predicting treatment response in rheumatoid arthritis.Intratumor heterogeneity of biomarker expression in breast carcinomas.Diagnostic and prognostic value of plasma and tissue ubiquitin-like, containing PHD and RING finger domains 1 in breast cancer patients.Gene therapy of malignant solid tumors by targeting erbB2 receptors and by activating T cells.Resistance to tamoxifen-induced apoptosis is associated with direct interaction between Her2/neu and cell membrane estrogen receptor in breast cancer.Tyrosine-317 of p52(Shc) mediates androgen-stimulated proliferation signals in human prostate cancer cells.Addition of anti-estrogen therapy to anti-HER2 dendritic cell vaccination improves regional nodal immune response and pathologic complete response rate in patients with ERpos/HER2pos early breast cancerPhosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer.Constitutive MEK/MAPK activation leads to p27(Kip1) deregulation and antiestrogen resistance in human breast cancer cells.Biomonitoring of urinary tamoxifen and its metabolites from breast cancer patients using nonaqueous capillary electrophoresis with electrospray mass spectrometry.ErbB2-overexpressing human mammary carcinoma cells display an increased requirement for the phosphatidylinositol 3-kinase signaling pathway in anchorage-independent growth.Gene expression for suppressors of telomerase activity (telomeric-repeat binding factors) in breast cancer.Phase III randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER/PgR-positive advanced breast cancer.
P2860
Q26752780-D2D271D3-8E9D-4930-8859-E3BED9A86707Q28084982-CFD0245B-3C4C-4623-93E9-BD2783E89BEBQ28504741-E5B9D00B-C6CF-4DE4-A4E5-7D82A314AAC0Q30857631-964647BB-FA22-4318-916E-43870BA877E9Q33571040-3B57A772-8F00-4B9D-A6D6-0D2B138E7070Q33664216-CA458E04-369B-4906-8D3D-B327B206447AQ33801908-2AE2AAF8-8EC2-4724-B1BB-37077D58DB2AQ34016364-D18382F3-28FD-40D6-98F3-6D99F7CCAF49Q34154147-7E69540D-F819-4287-B158-97DD6630DFA4Q34369138-1F1B0CF5-1916-421B-AC0B-05D5A6929431Q34424285-5AB67384-26E9-4E57-99E1-F73E11C8EBF1Q34713799-AC25AF91-8752-4915-8A88-F81C2AFE013DQ34998421-52713AD9-8E24-4157-94F1-3C9ED90D9921Q35023097-6BD22E25-68A4-4B97-B664-CD380332D77AQ35789355-092C62FE-4186-43A9-8F2D-F75317AC2C28Q35949291-87EC1D2E-81C1-4477-891E-615B0C054794Q36223407-FA8D3DB3-8924-4A45-9C48-EDA9A601EBE3Q36245537-48A88D47-1BCA-4684-BB29-CFF9549ABE56Q36643848-B89964C5-AAEF-45C5-8FEA-A4406423A1FDQ36653598-66F8D31C-2DC0-4854-96D5-5C0D50B578D2Q36657407-82C229EE-5116-4B78-982D-BB7DECA6EA0FQ36673777-32E9A7BB-6848-4676-9730-A86D83C8BF1BQ36721739-EB87C242-4ECE-48B2-B646-91EC63D471ECQ37247518-623DBEB4-7925-40D3-B189-A353876C585DQ37279308-3672F09D-2A05-4CEC-8488-F46B5D8FDF3CQ37467243-535DD7C3-E0C6-41DC-A240-5D3B42B18211Q37725973-1ED7566D-FECA-4DFE-ACAE-BAAA4D4FCB07Q38088942-BA47E7CF-9D48-4E51-9729-55B6BF675758Q38447114-8D8132C2-BC54-49E8-934A-8FA7C34EB92DQ39252224-0E787FB3-6786-4DA1-B8AB-AC346D423E7BQ39276348-4E5EF900-FA78-4C0D-9CCD-CAFEE2047425Q39411673-A337F440-AE1E-4CBC-B232-0944C578ADDAQ40584396-5F4904CE-4FFD-45E1-AA0C-80AA723DE53BQ41716752-A030FBF7-D9FC-4AA3-A4A0-AE57DFEB474CQ43635626-43F5C461-AF42-4D5A-884F-BEAD1A10EC1CQ43723448-F63CE489-237B-405B-80E4-299424763DCCQ43729839-621471F6-659F-4110-8688-5843E7EAB04BQ43800246-34D70057-000E-4568-A6DC-96F5C251DD65Q43942751-B332583F-3D33-4E05-ADF9-9B505F7B76ADQ44043976-7AB10AD4-9817-4487-8858-6AA98A37A750
P2860
Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Overexpression of c-erbB2 is a ...... apy in advanced breast cancer.
@ast
Overexpression of c-erbB2 is a ...... apy in advanced breast cancer.
@en
type
label
Overexpression of c-erbB2 is a ...... apy in advanced breast cancer.
@ast
Overexpression of c-erbB2 is a ...... apy in advanced breast cancer.
@en
prefLabel
Overexpression of c-erbB2 is a ...... apy in advanced breast cancer.
@ast
Overexpression of c-erbB2 is a ...... apy in advanced breast cancer.
@en
P2093
P2860
P356
P1476
Overexpression of c-erbB2 is a ...... apy in advanced breast cancer.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.BJC.6690196
P407
P577
1999-03-01T00:00:00Z